Myeloma cells suppress osteoblasts through sclerostin secretion

Blood Cancer Journal

Volumn 1, Issue 6, 2011, Pages

  Colucci, S ^a   Brunetti, G ^a   Oranger, A ^a   Mori, G ^b   Sardone, F ^a   Specchia, G ^a   Rinaldi, E ^a   Curci, P ^a   Liso, V ^a   Passeri, G ^c   Zallone, A ^a   Rizzi, R ^a   Grano, M ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Multiple myeloma; Myeloma cells; Osteoblasts; Osteolysis; Sclerostin

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; OSTEOPROTEGERIN; SCLEROSTIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUND;

ADULT; AGED; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL NUCLEUS; COCULTURE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOMA CELL; OSTEOBLAST; OSTEOLYSIS; PLASMA CELL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; UPREGULATION;

EID: 84864062016     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.22     Document Type: Article

References (37)

1. Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109: 283-291.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
4. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342. (Pubitemid 40852708)
6. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-2098. (Pubitemid 36302042)
7. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004; 104: 3722-3730. (Pubitemid 39564450)
8. Colucci S, Brunetti G, Mori G, Oranger A, Centonze M, Mori C et al. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia 2009; 23: 2139-2146.
9. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754. (Pubitemid 27516177)
10. Kern B, Shen J, Starbuck M, Karsenty G. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. J Biol Chem 2001; 276: 7101-7107.
11. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868. (Pubitemid 37383716)
12. Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 2004; 23: 2789-2799. (Pubitemid 39013551)
13. Bozec A, Bakiri L, Jimenez M, Schinke T, Amling M, Wagner EF. Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol 2010; 190: 1093-1106.
14. Nusse R. WNT targets. Repression and activation. Trends Genet 1999; 15: 1-3.
15. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997; 13: 157-162. (Pubitemid 27191521)
16. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM et al. LDL receptor related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107: 513-523. (Pubitemid 33152786)
17. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286-3305. (Pubitemid 28023954)
18. Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999; 18: 7860-7872. (Pubitemid 30066232)
19. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209.
20. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494. (Pubitemid 38010074)
21. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-3165. (Pubitemid 41565914)
22. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472-2483. (Pubitemid 41510822)
23. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665-7674. (Pubitemid 47281359)
24. Terpos E, Christoulas D, Gkotzamanidou M, Bratengeier C, Gavriatopoulou M, Migkou M et al. Circulating levels of the Wnt inhibitors Dickkopf-1 and sclerostin in different phases of multiple myeloma: alterations post-therapy with lenalidomide and dexamethasone with or without bortezomib. (ASH Annual Meeting Abstracts). Blood 2010; 116 (abstract 2963).
25. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005; 16: 319-327. (Pubitemid 40910321)
26. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199: 805-814. (Pubitemid 38375200)
27. Piters E, Culha C, Moester M, Van Bezooijen R, Adriaensen D, Mueller T et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat 2010; 31: E1526-E1543.
28. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537-543. (Pubitemid 32184286)
29. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002; 39: 91-97. (Pubitemid 34146376)
30. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002; 110: 144-152.
31. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26.
32. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-588.
33. Colucci S, Mori G, Vaira S, Brunetti G, Greco G, Mancini L et al. L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 2005; 76: 458-465. (Pubitemid 41185873)
34. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG. Wnt signalling in osteoblasts regulates expression of the receptor activator of NF kappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006; 119: 1283-1296.
35. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-2253.
36. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60: 3257-3262.
37. McCabe LR, Banerjee C, Kundu R, Harrison RJ, Dobner PR, Stein JL et al. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology 1996; 137: 4398-4408. (Pubitemid 26321890)